AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Research Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

The enhanced permeability and retention effect based nanomedicine at the site of injury

Yingjun Liu1,§, Dongdong Sun2,§, Qin Fan1, Qingle Ma1, Ziliang Dong1, Weiwei Tao2, Huiquan Tao1, Zhuang Liu1, Chao Wang1 ( )
Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou 215123, China
Collaborative Innovation Center of Jiangsu Province of Cancer Prevention and Treatment of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

§ Yingjun Liu and Dongdong Sun contributed equally to this work.

Show Author Information

Graphical Abstract

Abstract

The enhanced permeability retention (EPR) effect based nanomedicine has been widely used for tumor targeting during the past decades. Here we unexpectedly observed the similar "EPR effect" at the site of injury. We found that the temporary dilated and leaky blood vessels caused by the potent vasodilator histamine in response to injury allowed the injected nanoparticles to pass through the vasculature and reached the injured tissue. Our finding shows the potential underline mechanism of "EPR effect" at the injured site. By loading with antibiotics, we further demonstrated a new strategy for prevention of infection at the site of injury.

Keywords

enhanced permeability retention (EPR) effectinjured tissuepolymeric nanoparticleshistamineimmune response

Electronic Supplementary Material

Download File(s)
12274_2020_2655_MOESM1_ESM.pdf (2.4 MB)

References

[1]
Shi, J. J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20-37.
Crossref Google Scholar
[2]
Blanco, E.; Shen, H. F.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941-951.
Crossref Google Scholar
[3]
Chen, H. M.; Zhang, W. Z.; Zhu, G. Z.; Xie, J.; Chen, X. Y. Rethinking cancer nanotheranostics. Nat. Rev. Mater. 2017, 2, 17024.
Crossref Google Scholar
[4]
Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.
Crossref Google Scholar
[5]
Chen, H. B.; Gu, Z. J.; An, H. W.; Chen, C. Y.; Chen, J.; Cui, R.; Chen, S. Q.; Chen, W. H.; Chen, X. S.; Chen, X. Y. et al. Precise nanomedicine for intelligent therapy of cancer. Sci. China Chem. 2018, 61, 1503-1552.
Crossref Google Scholar
[6]
Pelaz, B.; Alexiou, C.; Alvarez-Puebla, R. A.; Alves, F.; Andrews, A. M.; Ashraf, S.; Balogh, L. P.; Ballerini, L.; Bestetti, A.; Brendel, C. et al. Diverse applications of nanomedicine. ACS Nano 2017, 11, 2313-2381.
Crossref Google Scholar
[7]
Youn, Y. S.; Bae, Y. H. Perspectives on the past, present, and future of cancer nanomedicine. Adv. Drug Deliv. Rev. 2018, 130, 3-11.
Crossref Google Scholar
[8]
Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392.
Google Scholar
[9]
Nel, A.; Ruoslahti, E.; Meng, H. New insights into “permeability” as in the enhanced permeability and retention effect of cancer nanotherapeutics. ACS Nano 2017, 11, 9567-9569.
Crossref Google Scholar
[10]
Pober, J. S.; Sessa, W. C. Inflammation and the blood microvascular system. Cold Spring Harb. Perspect. Biol. 2015, 7, a016345.
Crossref Google Scholar
[11]
Chen, L. L.; Deng, H. D.; Cui, H. M.; Fang, J.; Zuo, Z. C.; Deng, J. L.; Li, Y. L.; Wang, X.; Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018, 9, 7204-7218.
Google Scholar
[12]
White, M. Mediators of inflammation and the inflammatory process. J. Allergy Clin. Immunol. 1999, 103, S378-S381.
Google Scholar
[13]
Branco, A. C. C. C.; Yoshikawa, F. S. Y.; Pietrobon, A. J.; Sato, M. N. Role of histamine in modulating the immune response and inflammation. Mediators Inflamm. 2018, 2018, 9524075.
Google Scholar
[14]
Parham, P. The Immune System; Garland Science: New York, 2014.
[15]
Cotran, R. S.; Majno, G. The delayed and prolonged vascular leakage in inflammation. I. Topography of the leaking vessels after thermal injury. Am. J. Pathol. 1964, 45, 261-281.
Google Scholar
[16]
Cotran, R. S. The delayed and prolonged vascular leakage in inflammation. II. An electron microscopic study of the vascular response after thermal injury. Am. J. Pathol. 1965, 46, 589-620.
Google Scholar
[17]
Ryu, J. K.; McLarnon, J. G. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J. Cell. Mol. Med. 2009, 13, 2911-2925.
Google Scholar
[18]
Miles, A. A.; Wilhelm, D. L. The activation of endogenous substances inducing pathological increases of capillary permeability. In The Biochemical Response to Injury; Stoner, H. B.; Threlfall, C. J., Eds.; Blackwell: Semmering, Austria, 1960; pp 51-83.
[19]
Nourshargh, S.; Alon, R. Leukocyte migration into inflamed tissues. Immunity 2014, 41, 694-707.
Google Scholar
[20]
Dale, H. H.; Richards, A. N. The vasodilator action of histamine and of some other substances. J. Physiol. 1918, 52, 110-165.
Google Scholar
[21]
Heitz, D. C.; Brody, M. J. Possible mechanism of histamine release during active vasodilatation. Am. J. Physiol. 1975, 228, 1351-1357.
Google Scholar
[22]
Weissleder, R.; Nahrendorf, M.; Pittet, M. J. Imaging macrophages with nanoparticles. Nat. Mater. 2014, 13, 125-138.
Google Scholar
[23]
Chen, X. Y.; Wong, R.; Khalidov, I.; Wang, A. Y.; Leelawattanachai, J.; Wang, Y.; Jin, M. M. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials 2011, 32, 7651-7661.
Google Scholar
[24]
Song, G.; Petschauer, J. S.; Madden, A. J.; Zamboni, W. C. Nanoparticles and the mononuclear phagocyte system: Pharmacokinetics and applications for inflammatory diseases. Curr. Rheumatol. Revi. 2014, 10, 22-34.
Google Scholar
[25]
Chu, D. F.; Gao, J.; Wang, Z. J. Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano 2015, 9, 11800-11811.
Google Scholar
[26]
Pridgen, E. M.; Langer, R.; Farokhzad, O. C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2007, 2, 669-680.
Google Scholar
[27]
Mohamed, H. A.; Radwan, R. R.; Raafat, A. I.; Ali, A. E. H. Antifungal activity of oral (tragacanth/acrylic acid) amphotericin B carrier for systemic candidiasis: In vitro and in vivo study. Drug Deliv. Transl. Res.2018, 8, 191-203.
Google Scholar
[28]
López-Ribot, J. L.; Casanova, M.; Murgui, A.; Martínez, J. P. Antibody response to Candida albicans cell wall antigens. FEMS Immunol. Med. Microbiol. 2004, 41, 187-196.
Google Scholar
Nano Research
Volume 13 Issue 2,
February 2020
Pages 564-569
DOI: 10.1007/s12274-020-2655-6
Cite this article:
Liu Y, Sun D, Fan Q, et al. The enhanced permeability and retention effect based nanomedicine at the site of injury. Nano Research, 2020, 13(2): 564-569. https://doi.org/10.1007/s12274-020-2655-6
Topics:
Medical nanotechnologyNanoparticlesTissue

828

Views

62

Crossref

N/A

Web of Science

61

Scopus

4

CSCD

Altmetrics
Received: 30 September 2019
Revised: 30 December 2019
Accepted: 10 January 2020
Published: 24 January 2020
© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2020
Return